Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Longeveron Inc.

NASDAQ: LGVN · Life Sciences · 7 alerts · CIK 1721484

Share price
$2.14Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Longeveron Inc. filings on SEC EDGAR ↗

5:12 PM ET 8-K
Financial Results

Longeveron Financial Results

Longeveron Inc. reported Q3 2026 financial results and announced it has initiated a formal process to review strategic alternatives, including a potential sale, merger, or business combination. The company has retained Lucid Capital Markets as its financial advisor and is seeking a meeting with the FDA to discuss next steps for its HLHS program following Phase 2b trial results.

“With ELPIS II results now available, we have requested a meeting with the FDA to determine potential next steps for the HLHS development program. At the same time, we continue to review potential strategic alternatives for the Company as we explore all opportunities to maximize value for our stockholders.”

Stephen H. Willard, Chief Executive Officer
4:17 PM ET 10-Q
Financial Results

Longeveron Q3 2026 Results: Net Loss of $6.13M, Loss Narrows

For the nine months ended September 30, 2026, Longeveron Inc. reported a net loss of $16.9 million, a slight improvement from the $17.3 million loss in the prior year period. Total revenues decreased slightly to $0.8 million, while the company strengthened its cash position to $7.2 million through private placements and warrant exercises.

Key figure
Net loss $6.13M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.